Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Operating Leases (2023 - 2025)

Immunome (IMNM) has disclosed Operating Leases for 3 consecutive years, with $3.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases fell 19.17% year-over-year to $3.9 million, compared with a TTM value of $3.9 million through Dec 2025, down 19.17%, and an annual FY2025 reading of $3.9 million, down 19.17% over the prior year.
  • Operating Leases was $3.9 million for Q4 2025 at Immunome, down from $4.0 million in the prior quarter.
  • Across five years, Operating Leases topped out at $4.8 million in Q4 2024 and bottomed at $1.2 million in Q1 2024.
  • Average Operating Leases over 3 years is $3.2 million, with a median of $3.9 million recorded in 2025.
  • The sharpest move saw Operating Leases surged 255.9% in 2024, then decreased 19.17% in 2025.
  • Year by year, Operating Leases stood at $1.3 million in 2023, then soared by 255.9% to $4.8 million in 2024, then fell by 19.17% to $3.9 million in 2025.
  • Business Quant data shows Operating Leases for IMNM at $3.9 million in Q4 2025, $4.0 million in Q3 2025, and $4.1 million in Q2 2025.